AbbVie Inc. is 40.1x more valuable than ARROWHEAD PHARMACEUTICALS, INC. by market capitalization ($399.47 B vs $9.96 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ARWR | ABBV |
|---|---|---|
| Market cap | $9.96 B | $399.47 B |
| US-listed rank | #941 | #28 |
| Revenue (latest FY) | $829.45M | $61.16B |
| Net income (latest FY) | -$1.63M | $4.23B |
| Net margin | -0.2% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 1,347 | 1,008 |
AbbVie Inc. is 40.1x more valuable than ARROWHEAD PHARMACEUTICALS, INC. by market capitalization ($399.47 B vs $9.96 B).
In their latest fiscal years, ARROWHEAD PHARMACEUTICALS, INC. reported $829.45M in revenue while AbbVie Inc. reported $61.16B.
Full pages: ARROWHEAD PHARMACEUTICALS, INC. and AbbVie Inc., or browse the full rankings.